News Overview


Author: Debora Meier-Feutren
(l) Dr. Michael Hennig (CEO of leadXpro) & (r) Dr. Benno Rechsteiner (CEO of Switzerland Innovation Park Innovaare)
(l) Dr. Michael Hennig (CEO of leadXpro) & (r) Dr. Benno Rechsteiner (CEO of Switzerland Innovation Park Innovaare)

Did you like this article? Please share it.


Construction of the 23,000m2 new campus has begun. One month after the groundbreaking ceremony, leadXpro is the first company to ascertain its position in PARK INNOVAARE’s cutting-edge innovation infrastructure. Of the approximately 7,000m2 available rental space, leadXpro has contractually reserved more than 10%, guaranteeing its presence at the newly expanded innovation park when it opens in 2023. 

As stated on its website, leadXpro is a “drug discovery company focusing on membrane protein targets such as GPCR’s, ion-channels and transporters. Its technology platform capitalizes on the expert knowledge regarding membrane protein biochemistry and close collaboration with the Paul Scherrer Institute PSI for its synchrotron light source (SLS), X-ray Free Electron Laser (SwissFEL) as well as with the University of Basel’s Center for Cellular Imaging & Nano-Analytics (C-CINA) for its single particle cryo-electron microscopy (cryo-EM).” 

Dr. Benno Rechsteiner, CEO of PARK INNOVAARE, demonstrated his enthusiasm at the contractual settlement with the first tenant of the new campus: “I am thrilled to welcome leadXpro as the first of our member companies to guarantee their space in the new innovation campus.”

Prof. Dr. Michael Hennig, CEO of leadXpro, said after the contract signing: “We were one of the first companies to join PARK INNOVAARE, and today’s contract signing is a logical consequence of the vision we had to become part of the Innovation Park.”

Prof. Dr. Michael Hennig had more than 20 years of management experience in drug discovery research at F. Hoffmann-La Roche AG Basel before he co-founded leadXpro in 2015. He is guest professor for structural biology at the University of Basel.

Co-signatory Rafael Abela, PhD, member of leadXpro’s Board of Directors, was the Scientific leader of the Swiss Light Source (SLS) project and the project leader for photonics and research of the Swiss Free Electron Laser (SwissFEL) at the Paul Scherrer Institute PSI.




leadXpro & Switzerland Innovation Park Innovaare
Contract Signatories (l to r): Dr. Colonna (PARK INNOVAARE, Senior Project Manager Innovation & Funding), Dr. Abela (leadXpro, Board of Directors), Dr. Hennig (leadXpro, CEO), Dr. Rechsteiner (PARK INNOVAARE, CEO)

leadXpro is an emerging biotechnology company and has already established an impressive track record with discovery partnerships on membrane protein drug targets. Along this line, collaborations with Astex Pharmaceuticals and Lundbeck were announced in 2019. leadXpro is also committed to own innovative drug discovery and development projects to fight cancer and the ever more emerging antibiotics resistance. 

PARK INNOVAARE’s new buildings will comprise the following features: high-end offices; co-working spaces; prototype workshops; physics, biology & chemistry laboratories with an adaptable architectural design; ISO 5 and ISO 6 compliant cleanrooms; VC-E compliant vibration-controlled facilities; technical control rooms; cafeteria; underground parking lot; allocated bus stop, etc. etc. The companies will be co-located with Paul Scherrer Institute PSI, the main leaser.

For more information about rental possibilities, please contact Dr. Francesco Colonna at: